@targetedonc.bsky.social
"We're developing a RAS toolkit, not just one RAS drug....all of which are going to have some use in some combination with one another." - Benjamin Herzberg, MD, @columbiacancer.bsky.social Listen to the new episode of Targeted Talks: www.targetedonc.com/view/herzber...
ICYMI 🔎: An #FDA advisory panel has backed the Galleri MCED test for adults 50+, citing strong specificity, mixed sensitivity, and follow-up impacts as FDA weighs approval. Read more about the decision: targetedonc.com/view/fda-pan... #MCEDTest #CancerScreening #CancerDiagnosis
FDA Panel Votes in Favor of Galleri Multi-Cancer Early Detection Test | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Advisory panel backs Galleri blood test for adults 50+, citing strong specificity, mixed sensitivity, and follow-up impacts as FDA weighs approval.
targetedonc.com
Hans Lee, MD, @scri.com, talks about the new IMS/IMWG consensus on cure in myeloma from #IMS26 www.targetedonc.com/view/hans-le...
Dr Hans Lee on New IMS/IMWG Criteria for Defining Cure in Myeloma | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Hans Lee, MD, Sarah Cannon Research Institute, explains new IMS/IMWG cure criteria for myeloma and the meaning of durable CAR-T responses in these patients.
targetedonc.com
🚨 Conference update: Catch up with the final day of #IMS26 highlights www.targetedonc.com/view/ims-202...
https://www.targetedonc.com/view/ims-2026-day-4-mrd-guided-regimens-real-world-car-t-data
targetedonc.com
📢 ICYMI: The #FDA has approved lirafugratinib (Lyrfigtu) for adults with previously treated unresectable, locally advanced or metastatic #cholangiocarcinoma harboring an FGFR2 gene fusion or other rearrangement. Read more: targetedonc.com/view/fda-app... #Oncology #CancerTreatment
FDA Approves Lirafugratinib for FGFR2-Altered Cholangiocarcinoma | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
The oral FGFR2 inhibitor lirafugratinib is now FDA approved for the second-line treatment of cholangiocarcinoma harboring FGFR2 alterations.
targetedonc.com
We've recapped days 1 and 2 of #IMS26 @myeloma-society.bsky.social. Stay tuned for day 3! Day 1: www.targetedonc.com/view/ims-202... Day 2: www.targetedonc.com/view/ims-day...
IMS Day 1 Recap: Bispecific and CAR T Data Shape Myeloma Treatment | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Mezigdomide plus elranatamab yielded a 100% ORR in MELT-MM, as other IMS 2026 abstracts covered cevostamab, anito-cel vs cilta-cel, and linvoseltamab in HR-SMM.
targetedonc.com
From a presentation by Stefan Knop, MD: On-body injectors are preferred by both patients and HCPs, moving myeloma drug administration to a “fill, click, stick” model
We've landed in Glasgow and are ready for day 1 of #IMS26! Stay tuned this week for updates, interviews, and more from our team on the ground!
The FDA designates iza-bren as a breakthrough therapy for advanced EGFR-mutant NSCLC, promising improved outcomes for patients with limited options. Read the full story here → www.targetedonc.com/view/izalont...
Izalontamab Brengitecan Earns FDA Breakthrough Designation in EGFR+ NSCLC
The FDA designates iza-bren as a breakthrough therapy for advanced EGFR-mutant NSCLC, promising improved outcomes for patients with limited options.
hubs.li
New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive bladder cancer patients ineligible for cisplatin. Read more→ www.targetedonc.com/view/neoadju...
Neoadjuvant Pembrolizumab and Enfortumab Vedotin Improve Outcomes in MIBC
New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive bladder cancer patients ineligible for cisplatin.
targetedonc.com
The FDA has granted accelerated approval to #zongertinib in HER2+ #NSCLC. Read about the breaking regulatory decision here → www.targetedonc.com/view/fda-gra...
FDA Grants Accelerated Approval to Zongertinib in HER2 NSCLC
Zongertinib gains FDA approval for advanced NSCLC with HER2 mutations, showcasing promising efficacy and safety in clinical trials.
targetedonc.com
BREAKING NEWS: The FDA granted accelerated approval to dordaviprone (Modeyso) for adult and pediatric patients with diffuse midline glioma, marking a major step forward in this patient population. Read more about the approval here → www.targetedonc.com/view/dordavi...
Dordaviprone Receives Accelerated FDA Approval for Diffuse Midline Glioma
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
targetedonc.com
July marked a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment options for various cancers. Read up on all of the FDA happenings in our monthly recap: www.targetedonc.com/view/july-20...
July's Oncology Approvals: A Landmark Month for Cancer Treatment Advancements
July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment options for various cancers.
hubs.li
Game-changer in CLL/SLL? Pirtobrutinib's Phase 3 data reveals it's matching and potentially outperforming ibrutinib in ORR. Its noncovalent mechanism is key for overcoming resistance. A promising development for our clinical community. www.targetedonc.com/view/optimiz...
Optimizing CLL/SLL Therapy: Pirtobrutinib Matches Ibrutinib in Phase 3
Pirtobrutinib shows promising results in treating CLL, outperforming ibrutinib in a pivotal phase 3 trial, paving the way for broader applications.
targetedonc.com
Ateganosine has received FDA Fast Track designation for advanced NSCLC progressing after ICI therapy. This novel telomere-targeting agent is showing promising early clinical data. Explore the full article for insights into this critical development. www.targetedonc.com/view/ategano...
Ateganosine Receives FDA Fast Track Designation for NSCLC
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
targetedonc.com
Durvalumab just received FDA Priority Review & Breakthrough Therapy for resectable early-stage gastric/GEJ cancers. This could be the first perioperative immunotherapy in this setting, addressing a high unmet need. Read the full story here: www.targetedonc.com/view/durvalu...
Durvalumab Earns FDA Priority Review for Early-Stage Gastric Cancer
Durvalumab's breakthrough therapy designation offers hope for improved outcomes in early-stage gastric and GEJ cancers, potentially transforming treatment strategies.
targetedonc.com
FDA grants priority review to tabelecleucel for relapsed/refractory EBV+ PTLD, a critical step towards the first approved therapy for this severe posttransplant malignancy. PDUFA date Jan 10, 2026. #EBVPTLD #CellTherapy #FDA #Oncology www.targetedonc.com/view/fda-gra...
FDA Grants Priority Review to Tab-cel for EBV+ PTLD After Prior Therapies
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
targetedonc.com
The EU approved belantamab mafodotin (Blenrep) combinations in R/R multiple myeloma, enhancing treatment options for relapsed multiple myeloma patients with promising efficacy and safety profiles. Read the full story: www.targetedonc.com/view/eu-appr...
EU Approves Belantamab Mafodotin Combinations for Relapsed/Refractory Myeloma
The EU approves belantamab mafodotin combinations, enhancing treatment options for relapsed multiple myeloma patients with promising efficacy and safety profiles.
targetedonc.com
Luspatercept (Reblozyl) phase 3 INDEPENDENCE trial missed its primary endpoint for RBC transfusion independence but showed promising secondary benefits, like reduced transfusion burden & increased hemoglobin. hubs.li/Q03ycfyx0 #Myelofibrosis #Anemia #ClinicalTrials
Luspatercept Misses Primary End Point, Shows Clinically Meaningful Secondary Benefits
Luspatercept shows promise in improving anemia in myelofibrosis patients, despite not meeting primary trial endpoints, highlighting ongoing treatment challenges.
hubs.li
The FDA has issued a CRL for RP1 in advanced melanoma, primarily due to concerns about the interpretability of the IGNYTE trial's results and questions on the confirmatory trial design. This emphasizes the strict regulatory requirements for new therapies. www.targetedonc.com/view/fda-iss...
FDA Issues CRL for RP1 in Advanced Melanoma
Replimune faces FDA hurdles for RP1, an innovative melanoma treatment, as it seeks a path forward after receiving a complete response letter.
targetedonc.com
Final OS data from FLAURA2 confirm osimertinib + platinum-based chemo significantly extends survival in 1L EGFRm NSCLC. A potential new standard of care. Read more: hubs.li/Q03y1gxQ0 #LungCancer #EGFRm #NSCLC #Oncology #ClinicalTrials
Osimertinib Plus Chemotherapy Significantly Extends Survival in Advanced EGFRm NSCLC
Osimertinib plus chemotherapy significantly improves overall survival in EGFRm NSCLC, signaling a new standard of care.
hubs.li
FDA issues CRL for glofitamab + GemOx in 2L R/R DLBCL, citing limited US patient enrollment in STARGLO study. Glofitamab retains accelerated approval as monotherapy in later lines. Important regulatory update for clinicians. #Lymphoma #DLBCL #OncTwitter #FDA www.targetedonc.com/view/fda-iss...
FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy
FDA issues a complete response letter for glofitamab's second-line DLBCL indication, highlighting ongoing scrutiny in oncology therapy approvals.
targetedonc.com
Thank you, @targetedonc.bsky.social, for reporting on this subset analysis from the @swog.org S1826 trial, recently publ in JCO: Nivolumab Plus AVD Outperforms Brentuximab Vedotin-Based Regimen in Older Patients With Classic Hodgkin Lymphoma targetedonc.com/view/nivolum...
Nivolumab Plus AVD Outperforms Brentuximab Vedotin-Based Regimen in Older Patients With Classic Hodgkin Lymphoma
A recent trial reveals that nivolumab combined with chemotherapy significantly improves survival rates in older patients with advanced Hodgkin lymphoma.
targetedonc.com
BREAKING: The #FDA granted accelerated approval to datopotamab deruxtecan (Datroway) for adult patients with locally advanced or metastatic EGFR-mutated #NSCLC who have previously received systemic therapies, including EGFR-targeted treatments. www.targetedonc.com/view/fda-gra...
FDA Grants Accelerated Approval to Dato-DXd in Previously Treated EGFR+ NSCLC
FDA accelerates approval of datopotamab deruxtecan for advanced EGFR-mutated NSCLC, offering new hope for previously treated patients.
targetedonc.com
#ASCO25 Recap: Immunotherapy takes center stage! Dr. David Spigel shares the key highlights. ▶️ Watch now! #CancerTreatment #SarahCannon
Follow along for real-time updates from #ASCO25 and insights from the ground floor of the world’s leading oncology conference! www.targetedonc.com/conference/a... #OncologyInnovation #MedicalOncology #CancerResearch #PrecisionMedicine
Anlotinib showed noninferior PFS vs bevacizumab when either agent was combined with first-line CapeOX chemotherapy in Chinese patients with RAS/BRAF wild-type, unresectable #mCRC, meeting the primary end point of the phase 3 ANCHOR trial. #crcsm #ASCO25 www.targetedonc.com/view/anlotin...
Anlotinib Noninferior to Bevacizumab in Frontline RAS/BRAF Wild-Type mCRC
Anlotinib plus chemotherapy has emerged as a first-line alternative to bevacizumab/chemotherapy in RAS/BRAF wild-type metastatic colorectal cancer.
targetedonc.com
Big news from the May 21 #ASCO25 press briefing: 🔹 GLP-1s show cancer risk reduction 🔹 AI boosts HER2-low scoring accuracy 🔹 Inavolisib triplet extends survival in PIK3CA-mutant breast cancer 🔹 Lurbinectedin combo shows OS/PFS gains in SCLC www.targetedonc.com/view/asco-20...
ASCO 2025 Briefing: Advances in Breast, Lung, and Obesity-Linked Cancers
The ASCO 2025 press briefing showcased early highlights in cancer therapy. Here’s what you need to know.
targetedonc.com
